Acquired resistance to LY2874455 in <i>FGFR2</i>-amplified gastric cancer through an emergence of novel <i>FGFR2-ACSL5</i> fusion
Sun Young Kim(Ulsan College), Jeeyun Lee(Samsung Medical Center)
Cited by 46
Related Papers
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|614
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
|Annals of Oncology|2018|105
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
|Seoul National University Open Repository (Seoul National University)|2021|95
ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC).
|Journal of Clinical Oncology|2019|79
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
|Oncotarget|2015|61